Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8204606 | 0.82 | TAAR1 (0.73) | TAAR1 | |
| SCHEMBL4894114 | 0.80 | TAAR1 (0.47) | TAAR1HRH3FNTAFNTBPGGT1B | |
| SCHEMBL8211275 | 0.76 | TAAR1 (0.71) | TAAR1HRH3 | |
| SCHEMBL8204601 | 0.72 | TAAR1 (0.74) | TAAR1 | |
| SCHEMBL4894175 | 0.72 | SSTR4 (0.45) | TAAR1FNTAFNTBPGGT1BGBA1 | |
| SCHEMBL632033 | 0.71 | TAAR1 (0.68) | TAAR1FNTAFNTB | |
| SCHEMBL10228947 | 0.69 | TAAR1 (0.63) | TAAR1 | |
| SCHEMBL10227197 | 0.69 | TAAR1 (0.60) | TAAR1 | |
| SCHEMBL631943 | 0.68 | TAAR1 (0.73) | TAAR1 | |
| SCHEMBL10229128 | 0.68 | TAAR1 (0.73) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | UNIVERSITY OF WASHINGTON (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | AKR1C3, NR1H3, HCCS | TAAR1 3105/4885HRH3 365/4885FNTA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.